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OBJECTIVES: CLL is a common form of leukaemia associated
with symptoms of tiredness, night sweats, weight loss, anaemia
and infection. The objective of this study was to measure the
comparative utility of eight disease states describing two ﬁrst line
treatments (MabCampath, chorambucil) and the progression-
free and progressive stages of CLL following ﬁrst, second and
ﬁnal lines of therapy. METHODS: In order to obtain societal
preferences, we conducted a utility study in the UK with 60
members of the general public using the Time Trade-Off (TTO)
method. The interviews were conducted face-to-face by trained
interviewers using a TTO scale with a 10 year duration period. A
Visual Analogue Scale (VAS) (0 being death and 100 being full
health) was also included. Information on the condition and
health states were developed using literature, in-depth interviews
and validation with specialist nurses and a specialist physician.
RESULTS: The mean utility scores according to the TTO were:
progression-free after ﬁrst-line therapy; 0.777, progressive after
ﬁrst-line therapy; 0.540, progression-free after second-line
therapy; 0.650, progressive after second-line therapy; 0.470,
progression-free after ﬁnal-line therapy; 0.428 and progressive
after ﬁnal-line therapy; 0.279. The mean utility on ﬁrst-line treat-
ment was 0.619 for MabCampath and 0.623 for chlorambucil.
The VAS scores had similar values. CONCLUSIONS: In conclu-
sion, there was gradual decline in the utility score after each
subsequent line of therapy for patients in progression-free states
and for patients in progressive states. Utility decreased when
patients moved from progression-free to progressive states after
each line of therapy. These values can be used in cost-utility
analyses of treatment pathways associated with CLL.
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OBJECTIVES: To compare patient reported quality of life in
cancer patients on opioid therapy with and without constipation.
METHODS: Patients with a diagnosis of cancer, receiving
opioids from all public pharmacies in The Netherlands, were
recruited by a pharmacy worker to complete a generic question-
naire about opioid use and constipation and the EuroQoL-5-
Dimensions questionnaire (EQ-5D) about generic Quality of Life
(QoL). Patients were classiﬁed as having constipation or not
based on self-reported bothersome side effect of the opioid and
use of laxatives. EQ-5D index scores were compared with Wil-
coxon Two-group test. RESULTS: A total of 113 patients using
opioids from 170 pharmacies returned the questionnaires.
Seventy-ﬁve (66%) of the cancer patients were classiﬁed as
having constipation. Patients with and without constipation were
similar with respect to age (mean  standard deviation
66.1  9.8 and 63.8  12.6, respectively), gender (44% and
50% males, respectively) and type of opioid (most frequently
oxycodone, fentanyl and morphine preparations in both groups).
Patients with constipation more often reported problems with
Pain (95% versus 92%) and Anxious/depressed Mood (52% vs.
42%), but less often with Self care (52% vs. 58%) than patients
without constipation. The median [25th–75th percentile] EQ-5D
index score among patients with constipation was lower com-
pared to those without constipation (0.39 [0.19–0.69] vs. 0.63
[0.30–0.78], p = 0.10). CONCLUSIONS: Constipation in cancer
patients using opioids has a substantial impact on patient’s
quality of life. Alleviation of constipation symptoms might help
improve patient reported quality of life.
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OBJECTIVES: To carry out a cross-cultural adaptation into
Spanish of the UCLA-PCI questionnaire and to validate a
reduced version. METHODS: Firstly, forward-backward trans-
lations of the UCLA-PCI were made by two native (English and
Spanish) translators and integrated into a preliminary version by
an expert panel (two urologists and one radiologist). Compre-
hension of items was analyzed by 15 prostatic cancer (PC)
patients by using a 4 levels likert scale. As a result, an initial
version (UCLA-PCI 1.0) was reached by consensus. Next, 50 PC
patients who had received treatment (radiotherapy or prostatec-
tomy) 3 years before answered both the UCLA-PCI 1.0 and the
generic HRQoL questionnaire SF-12 Health Survey. Exploratory
factorial analysis -FA-, item-total correlations and conﬁrmatory
FA (promax oblique rotation) were applied to reduce the UCLA-
PCI 1.0 into a 4 items scale (UCLA-PCI-brief). Internal consis-
tency (Cronbach’s a), feasibility and convergent validity
(Spearman correlation with SF-12 and non parametric test for 2
independent samples, according to TNM tumor stage) were
assessed. RESULTS: Internal consistency was high in UCLA-PCI
1.0 (0.856) and acceptable in UCLA-PCI-brief (0.731). UCLA-
PCI 1.0 FA showed the same constructs that the original (urinary,
bowel and sexual symptoms—function and bother). UCLA-PCI-
brief FA revealed 3 functional dimensions: urinary (2 items;
56.16 of variance explained), bowel (1 item, 21%), intestinal (1
item, 15.28%). Moreover, correlations between UCLA-PCI–brief
and SF-12 Mental and Physical Summaries Components were
respectively: urinary (0.31 and 0.38; p > 0.05), intestinal (0.29
and 0.634; p < 0.05) and sexual (0.04 and 0.33; p > 0.05).
Finally, signiﬁcant differences were found in the UCLA-PCI
scores between patients with a more favorable PC stage and
patients with a worse prognosis. CONCLUSIONS: The Spanish
version of the UCLA-PCI maintains the same structure as the
original. An item reduced version (UCLA-PCI-brief) with
adequate properties has been developed.
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TESTINGTHE MEASUREMENT EQUIVALENCE OF PAPER
AND INTERACTIVEVOICE RESPONSE (IVR) VERSIONS OF
THE EQ-5D
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OBJECTIVES: Electronic data capture technologies, such as
interactive voice response (IVR) systems, are emerging as impor-
tant alternatives for collecting patient-reported outcomes data.
The objective of this study was to assess the measurement equiva-
lence of an IVR version of the EQ-5D with the original paper
version. METHODS: This study utilized a crossover design with
subjects randomly assigned to one of two assessment orders: 1)
paper then IVR or 2) IVR then paper. A convenience sample of
in-treatment outpatient cancer clinic patients (n = 139) were
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